Nivolumab significantly improved disease-free survival (DFS) compared to placebo in both the intention-to-treat population (HR 0.70; p < 0.001) and patients with tumor PD-L1 expression ≥ 1% (HR 0.55; p < 0.001) [22]. The gene discussed is CD274; the disease is neoplasm.